

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.1. Cytotoxic medicines

Indication Medicine type List type Formulations EML status history Sex Age	Lymphoid leukaemia, not elsewhere classified ICD11 code: 2C03.3 Biological agent Core (EML) (EMLc) Parenteral > General injections > unspecified: 10000 IU in vial powder for injection First added in 2015 (TRS 994) All
Formulations EML status history Sex	Core (EML) (EMLc) Parenteral > General injections > unspecified: 10000 IU in vial powder for injection First added in 2015 (TRS 994)
Formulations EML status history Sex	Parenteral > General injections > unspecified: 10000 IU in vial powder for injection First added in 2015 (TRS 994)
EML status history Sex	First added in 2015 (TRS 994)
Sex	
	All
Age	
	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents.
Tags	Biological
Wikipedia	Asparaginase 🗹
DrugBank	Asparaginase 🖸

Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for asparaginase on the complementary list of the EML and EMLc for use in treatment protocols for acute lymphoblastic leukaemia (ALL) was recommended. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for ALL is attached.

Expert Committee report **N**



